Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-05-15

Research on breast cancer aimed at identifying unique antigens and at developing antibodies

Objetivo

The department of Oncology of Crucell Holland BV, lead by Renate Zwijsen (PhD) is actively involved in the development and the commercialisation of monoclonal human antibodies, applying its MAbstract target discovery and antibody development technology and its PER.C6 human cell line technology for high-yielding antibody production.

The department of Oncology intends on initiating a breast cancer research program aimed specifically at identifying antigens that are uniquely expressed in breast cancer and, thereafter, at developing human antibodies that selectively bind to these identified antigens. For this project, Crucell Holland BV has an exclusive arrangement with the University Medical Centre of Utrecht (UMC Utrecht) through which Crucell Holland BV will have a constant supply of fresh breast cancer tissue samples to be used for this research project.

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Datos no disponibles

Convocatoria de propuestas

IHP-MCHI-01-1
Consulte otros proyectos de esta convocatoria

Régimen de financiación

Datos no disponibles

Coordinador

CRUCELL HOLLAND B.V.
Aportación de la UE
Sin datos
Dirección
Archimedesweg 4
LEIDEN
Países Bajos
Coste total
Sin datos